期刊论文详细信息
Frontiers in Immunology | |
Corrigendum: The efficacy and safety analysis of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinoma | |
Immunology | |
Tong Wang1  Xiaoying Qian1  Yong Li1  Xinwei Zhang1  Biao Yu1  Shangkun Yuan1  Yong Wang1  Renfang Chen1  Chen Fang1  Zhimin Zeng2  Anwen Liu2  Yan Yin3  Fanrong Liu4  Yong Yuan5  | |
[1] Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China;Medical Innovation Center, The First Affiliated Hospital of Nanchang University, Nanchang, China;Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China;Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang, Jiangxi, China;Radiation Induced Heart Damage Institute of Nanchang University, Nanchang, Jiangxi, China;Department of Pathology, The First Affiliated Hospital of Nanchang University, Nanchang, China;Department of Pathology, The Second Affiliated Hospital of Nanchang University, Nanchang, China;Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China; | |
关键词: pulmonary sarcomatoid carcinoma; immune checkpoint inhibitors; immunotherapy; anlotinib; camrelizumab; tislelizumab; | |
DOI : 10.3389/fimmu.2023.1269596 | |
received in 2023-07-30, accepted in 2023-08-24, 发布年份 2023 | |
来源: Frontiers | |
【 摘 要 】
【 授权许可】
Unknown
Copyright © 2023 Zeng, Qian, Liu, Wang, Yuan, Fang, Zhang, Yuan, Chen, Yu, Wang, Yin, Li and Liu
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202310122995871ZK.pdf | 244KB | download |